Pablo Mora, MD, is the lead author of two new articles published in The Lancet. The articles report Phase 2 results for zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist being studied in adults with type 2 diabetes. Across cohorts, both once-weekly subcutaneous and once-daily oral formulations produced substantial … Read more
Tekton’s Principal Investigators are practicing physicians whose clinical experience and established patient relationships shape how we evaluate protocols and collaborate with Sponsors and CROs from the earliest stages of a study. On Tuesday, August 4, from noon to 1 p.m. ET, Jara McDonald, MD, FAAFP, DABOM, CPI, will present during … Read more
A new video featuring Pablo Mora, MD, FACE, MSc, CDCES, is now available in the Novo Nordisk ScienceHub. Dr. Mora provides an overview of the Phase 2 results for investigational zenagamtide (amycretin) in adults with type 2 diabetes. The findings were recently presented at the American Diabetes Association Scientific Sessions. … Read more
Tekton Research and Summit Clinical Research Solutions Expand Partnership, Bring MASH Trials to Ohio
Key Information New Carlisle, Ohio site will conduct MASH trials under Ashok Devatha, MD Embedded urgent care operation provides a high-traffic clinical access point, supported by Dr. Devatha’s primary care relationships Collaboration builds on July 2025 launch of the partnership in Yukon, Oklahoma Tekton Research, a multi-specialty clinical research site … Read more
Tekton Research is pleased to share that its sites are part of Allucent’s newly launched IGNITE™ Site Network, a global network of pre-qualified clinical research sites designed to support greater speed, quality, and predictability in clinical trial delivery. IGNITE brings together sites aligned around therapeutic expertise, defined execution commitments, and … Read more
Site Selection Perspectives for Cardiometabolic and CNS Clinical Trials The Research Triangle is one of the most concentrated pharma and biotech ecosystems in the country. The companies headquartered there are running some of the most complex and consequential clinical trials in the industry today, particularly in cardiometabolic disease and neuroscience, two therapeutic … Read more
Every treatment, therapy, and medical breakthrough begins with people. People willing to ask questions. People willing to care deeply. People willing to show up every day to move medicine forward. This Clinical Trials Day, we’re celebrating the people behind the progress at Tekton Research: the coordinators, investigators, site managers, nurses, … Read more
As CNS capabilities expand, Tekton adds seasoned leadership to accelerate growth and execution AUSTIN, TX – May 6, 2026 – Tekton Research, a leading multi-site clinical trial organization with 25 research sites across North America, today announced the appointment of Amit Vijapura, MD as a Central Nervous System (CNS) Key … Read more
Featuring: Lori Elliot, Director of Budgets & Contracts In clinical research, speed matters. But not speed for speed’s sake. Speed without sacrificing discipline or site sustainability. Speed that ultimately gets patients access to new therapies sooner. At Tekton Research, contracting and budgeting is not an administrative afterthought. It is a … Read more
CNS (central nervous system) trials are some of the most complex-and most meaningful-studies in clinical research today. A recent Society for Clinical Research Sites (SCRS) SCRS Talks episode featuring Tekton’s Jeffrey Zucker and Brandon Lenfest explored the realities of conducting CNS trials-from patient identification to caregiver impact. In this article, we revisit the most compelling … Read more
Subscribe to Inside Tekton on LinkedIn
Get Tekton's monthly newsletter that rounds up the latest from Tekton, and the clinical research landscape.